Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O'Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company's strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O'Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company's strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O'Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company's strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O'Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company's strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O'Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company's strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November 2016 on Tuesday, 25 April 2017.

Analyst briefing

A briefing for analysts only will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25 April 2017.

Investor presentation

Stephen O'Hara will be giving a presentation for investors on the afternoon of Tuesday 25 April 2017 in the Grill room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start. The presentation will outline the Company's strategy to deliver value for shareholders and give an update for the year. This will be followed by light refreshments and an opportunity to network.

If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.